(Alliance News) - Tissue Regenix Group PLC on Thursday said it has launch a product line extension, DermaPure Non-Oriented, specifically tailored for the surgical and trauma markets.
DermaPure Non-Oriented, processed utilizing the company's patented dCELL technology, has two identical sides, meaning the orientation of the graft is not a factor during application or implantation. This will enhance ease of application, whilst also maintaining the acellular scaffold and thereby promoting tissue regeneration.
The regenerative medical devices company said the primary indication for this product line will be uro-gynecological procedures, where Tissue Regenix already has a working relationship with partner and distributor, ARMS Medical.
"Our commercial success is predicated on our ability to identify new clinical applications and rapidly develop product lines to meet this demand," said Interim Chief Executive Gareth Jones.
"We continue to see the growing demand for DermaPure, as demonstrated in our recent interim results, and expect that DermaPure Non-Oriented will augment this product portfolio, driving adoption by physicians in the future," added Jones.
Tissue Regenix shares were trading 3.6% lower on Thursday in London at 3.18 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
Tissue Regenix Group (TRX)